***  For details on how to be removed from this list visit the  ***
***          CCP4 home page http://www.ccp4.ac.uk         ***


Postdoc on Cytochrome P450 structural studies
Protein Crystallographer - AstraZeneca,Mölndal

AstraZeneca is now looking for a PhD crystallographer with hands on
experience in protein characterisation and crystallisation. This three year
post-doc position will be placed in the crystallography group at the
Structural Chemistry Laboratory at AstraZeneca R&D Mölndal, Sweden.

The Structural Chemistry Laboratory, Mölndal is a centre of excellence
supporting the AstraZeneca discovery organizations in Sweden, UK and US. 
The laboratory has around 35 scientists engaged in experimental research and
the core disciplines are protein crystallography, protein engineering and
NMR spectroscopy. The lab is excellently equipped with state of the art
equipment. Recently a full set of robotics has been installed to support the
process from protein crystallization to data collection. This is an
excellent opportunity for a structural scientist to gain experience from the
international and multidisciplinary environment within one of the worlds
leading pharmaceutical companies.

The successful candidate will be responsible for structural studies of
several human P450 isoforms in complex with substrates and inhibitors. The
candidate should have a strong genuine interest in studying molecular
interactions by crystallography. Experience with cytochrome P450 enzymes is
advantageous but not essential. The work includes close interactions with
project teams at the various AstraZeneca research sites. A natural talent to
interact in a team as well as the ability to communicate efficiently are
therefore required. 

For additional information, please contact Helena Käck AstraZeneca, +46 708
467091, [EMAIL PROTECTED]

Please send your application and CV marked "71-11715 Protein
Crystallographer" no later than July 16th via "apply now"
www.astrazeneca.com We will only consider applications received via our
website.

Reply via email to